CINECA IRIS Institutional Research Information System

PETRINI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 56.625
AS - Asia 23.348
EU - Europa 20.751
SA - Sud America 3.368
AF - Africa 934
Continente sconosciuto - Info sul continente non disponibili 891
OC - Oceania 62
Totale 105.979
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 52.617
CN - Cina 7.031
SG - Singapore 6.913
IT - Italia 6.703
SE - Svezia 3.676
HK - Hong Kong 3.600
CA - Canada 3.530
BR - Brasile 2.813
DE - Germania 2.033
VN - Vietnam 1.971
BG - Bulgaria 1.641
GB - Regno Unito 1.225
TR - Turchia 1.175
PL - Polonia 1.060
FI - Finlandia 862
UA - Ucraina 843
FR - Francia 818
RU - Federazione Russa 768
KR - Corea 564
IN - India 506
JP - Giappone 392
CH - Svizzera 350
CI - Costa d'Avorio 329
BD - Bangladesh 238
AT - Austria 197
AR - Argentina 157
IQ - Iraq 152
MX - Messico 152
BE - Belgio 150
SN - Senegal 127
PK - Pakistan 109
ZA - Sudafrica 99
NG - Nigeria 93
SA - Arabia Saudita 93
UZ - Uzbekistan 85
ID - Indonesia 83
NL - Olanda 80
EC - Ecuador 79
CO - Colombia 77
VE - Venezuela 71
CR - Costa Rica 68
JM - Giamaica 68
ES - Italia 65
MA - Marocco 57
EG - Egitto 53
KE - Kenya 50
CL - Cile 46
AU - Australia 45
PH - Filippine 40
AE - Emirati Arabi Uniti 38
IL - Israele 38
PY - Paraguay 38
MY - Malesia 36
UY - Uruguay 34
JO - Giordania 33
NI - Nicaragua 33
CZ - Repubblica Ceca 32
LT - Lituania 30
HN - Honduras 29
IE - Irlanda 28
BJ - Benin 25
PE - Perù 25
PT - Portogallo 25
TN - Tunisia 25
QA - Qatar 24
AZ - Azerbaigian 23
NP - Nepal 23
OM - Oman 22
TH - Thailandia 22
BO - Bolivia 19
EE - Estonia 19
KZ - Kazakistan 19
TT - Trinidad e Tobago 19
GR - Grecia 18
DZ - Algeria 16
HU - Ungheria 16
IR - Iran 16
PS - Palestinian Territory 16
DK - Danimarca 15
DO - Repubblica Dominicana 14
GT - Guatemala 14
RO - Romania 14
ET - Etiopia 13
SI - Slovenia 13
SV - El Salvador 13
EU - Europa 12
AL - Albania 11
BY - Bielorussia 11
PA - Panama 11
BB - Barbados 10
CY - Cipro 10
LB - Libano 10
RS - Serbia 10
CG - Congo 9
KG - Kirghizistan 9
MD - Moldavia 9
BS - Bahamas 8
GE - Georgia 8
LV - Lettonia 8
PR - Porto Rico 8
Totale 104.935
Salva come PNG Salva come JPEG
Città #
Woodbridge 5.317
Ashburn 4.976
Ann Arbor 4.260
Singapore 3.841
Hong Kong 3.552
Fairfield 3.517
Houston 3.349
Chandler 2.935
San Jose 2.678
Santa Clara 2.596
Montreal 2.357
Serra 2.357
Dallas 1.814
Milan 1.720
Sofia 1.627
Seattle 1.566
Beijing 1.534
Shanghai 1.364
Wilmington 1.264
Cambridge 1.158
Jacksonville 1.130
New York 1.089
Council Bluffs 987
Ottawa 955
Boardman 810
Hefei 781
Princeton 760
Izmir 742
Los Angeles 728
Lawrence 619
Medford 581
Lauterbourg 560
Seoul 550
Nanjing 520
Ho Chi Minh City 420
Des Moines 395
Dearborn 379
Tokyo 348
Dong Ket 329
Abidjan 328
Bern 319
Istanbul 309
Florence 304
Hanoi 288
Buffalo 282
Munich 260
São Paulo 254
Nanchang 237
Lancaster 229
London 212
San Diego 206
Jüchen 197
Rome 197
Redondo Beach 189
Helsinki 171
Frankfurt am Main 169
Vienna 168
Redwood City 160
Boulder 151
Brussels 147
Pisa 141
Bremen 137
Chicago 137
Kunming 137
Columbus 130
Dakar 127
The Dalles 123
Orem 119
Shenyang 117
Hebei 105
Changsha 103
Washington 100
Lagos 90
Phoenix 90
Ogden 88
Rio de Janeiro 87
Turku 82
Jiaxing 80
Fuzhou 77
Tashkent 77
Westminster 74
Pune 70
Düsseldorf 69
San Francisco 69
Tianjin 68
Toronto 68
Brooklyn 67
Da Nang 67
Norwalk 64
Dhaka 63
Warsaw 63
Belo Horizonte 62
Falls Church 62
Atlanta 61
Chennai 60
Guangzhou 60
Denver 59
Hangzhou 55
Baghdad 52
Nürnberg 52
Totale 74.654
Salva come PNG Salva come JPEG
Nome #
EFFICACY AND TOXICITY PROFILES OF LOW-DOSE THALIDOMIDE AS MAINTENANCE THERAPY IN MULTIPLE MYELOMA PATIENTS AFTER DOUBLE OR TRIPLE AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. 3.426
ZINC ORAL SUPPLEMENTATION INDUCES A SIGNIFICANT RISE OF TRECS AND T CD4+ NAΪVE AND PREVENTS THE INCREASE OF TTV VIRAL LOAD AFTER STEM CELL TRANSPLANTATION: THE ZENITH STUDY 446
ROLE OF GENETIC POLYMORPHISMS ON RESPONSE TO R-CHOP REGIMEN IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY 410
1,25(OH)2D3 and TPA in vitro activity on B-CLL. 295
Kinetics of hematogones in bone marrow samples from patients with non-Hodgkin lymphomas treated with rituximab-containing regimens: a flow cytometric study 284
How Nanotechnology Can Really Improve the Future of Orthopedic Implants and Scaffolds for Bone Defects 273
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study 273
CD57 expression on lymphoma microenvironment as a new prognostic marker related to immune dysfunction 272
Pore Size Distribution and Blend Composition Affect In Vitro Prevascularized Bone Matrix Formation on Poly(Vinyl Alcohol)/Gelatin Sponges 271
B-cell acute lymphoblastic leukemia with t(4;11)(q21;q23) in a young woman: evolution into mixed phenotype acute leukemia with additional chromosomal aberrations in the course of therapy. 270
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases 264
Is binding of vitamin D binding protein related to cell differentiation? 260
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk 258
Atypical APL including multiple translocations and abnormal response to micronuclei induction test 252
EVALUATION OF RESISTANCE INDEX OF SEVERAL ANTICANCER AGENTS ON PARENTAL AND RESISTANT P-388 CELL LINES 251
Inferential mining for reconstruction of 3D cell structures in Atomic Force Microscopy imaging 250
Identification of miRSNPs associated with the risk of multiple myeloma 248
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. Leuk Lymphoma 247
INDOMETHACIN INHIBITION OF BONE-MARROW GRANULOCYTE RELEASE INTO PERIPHERAL-BLOOD 246
Mesenchymal Stromal Cell Culture and Delivery in Autologous Conditions: A Smart Approach for Orthopedic Applications 245
Alternating chemotherapy regimen (P-VABEC) for intermediate and high-grade non-Hodgkin's lymphoma of the middle aged and elderly. 243
Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells 242
Bone marrow infiltration in B-cell non-Hodgkin's lymphomas: comparison between flow cytometry and bone marrow biopsy, RECENTI PROGRESSI IN MEDICINA 241
Glycosylation interference on RhoA activation: focus on G-CSF 241
CD45 expression in low-grade B-cell non-Hodgkin's lymphomas 240
New approaches for imaging and therapy of solid cancer 239
Plasticity of human dental pulp stromal cells with bioengineering platforms: A versatile tool for regenerative medicine. 239
IN THE CHRONIC MYELOID LEUKEMIA THE SALIVARY PROTEOMICS RECAPITULATES SOME ASPECTS OF THE LEUKEMIC STEM CELL. LA CELLULA STAMINALE LEUCEMICA E LA PROTEOMICA SALIVARE: IL MODELLO DELLA LEUCEMIA MIELOIDE CRONICA 237
Bone tissue engineering: Natural origination or synthetic polymeric scaffolds? 236
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases 233
Barium Titanate Nanoparticles: Highly Cytocompatible Dispersions in Glycol-chitosan and Doxorubicin Complexes for Cancer Therapy. 232
Specific integrin expression is associated with podosome-like structures on mesodermal progenitor cells. 231
Expression of MDR1, MRP, TOPOISOMERASE-IIa, TOPOISOMERASE-IIb and GSTp in acute leukemias. 229
Processing large-diameter poly(L-lactic acid) microfiber mesh/mesenchymal stromal cell constructs via resin embedding: an efficient histologic method 229
CHEMOIMMUNOTHERAPY REGIMEN OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB FOLLOWED BY ALEMTUZUM- AB AS INITIAL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A VALID APPROACH FOR ERADICATION OF MINIMAL RESIDUAL DISEASE 228
Identification and purification of mesodermal progenitor cells from human adult bone marrow. 228
1,25-Dihydroxyvitamin D3-mediated inhibition of human leukemic B cell precursors 227
Novel biological/biohybrid prostheses for the ossicular chain: fabrication feasibility and preliminary functional characterization 227
MESENCHYMAL CELLS INHIBIT IL2 AND ZOLENDRONATE-INDUCED ?/d T-LYMPHOCYTES 225
Growing bone tissue-engineered niches with graded osteogenicity: an in vitro method for biomimetic construct assembly 225
Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. 224
Treatment of oral mucositis in hematologic patients undergoing autologous or allogeneic transplantation of peripheral blood stem cells: a prospective, randomized study with a mouthwash containing Camelia Sinensis leaf extract 223
A rare case of de novo CD5+ diffuse large B-cell lymphoma in leukemic phase and positive for CD13 223
Tympanic Membrane Collagen Expression by Dynamically Cultured Human Mesenchymal Stromal Cell/Star-Branched Poly(ε-Caprolactone) Nonwoven Constructs 223
INTRA-LYMPHOCYTIC ADENOSINE-DEAMINASE AND PURINE NUCLEOSIDE PHOSPHORYLASE-ACTIVITY IN CHRONIC LYMPHOCYTIC-LEUKEMIA - EFFECT OF THYMOSTIMULIN 222
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 222
Alteraciones funcionales de los granulocitos neutrofilos en un joven neutropenico de raza negra 221
Infliximab treatment of grade IV skin acute graft versus host disease 221
Investigation of interactions between poly-L-lysine-coated boron nitride nanotubes and C2C12 cells: up-take, cytocompatibility, and differentiation 221
Autoimmune diseases and myeloid hematological disorders: a possible pathogenetic relationship 221
Modifications in B-Lymphocyte Number and Phenotype in the Course of Pregnancy in a Woman with Persistent Polyclonal B-Cell Lymphocytosis: A Flow Cytometric Study 220
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia 220
Low-dose ARA-C and 1(OH) D3 administration in acute non lymphoid leukemia: pilot study. 219
Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment 219
Could age modify the effect of genetic variants in IL6 and TNF-a genes in multiple myeloma? 218
Mesangiogenic Progenitor Cells Derived from One Novel CD64brightCD31brightCD14neg Population in Human Adult Bone Marrow 218
Constitutive expression of pluripotency-associated genes in mesodermal progenitor cells (MPCs) 217
Adenosine deaminase activity in human cord blood lymphocyte subpopulations. 216
Vitamin D binding protein is produced by human monocytes 216
EFFICACY OF FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (FCR) REGIMEN FOL- LOWED BY ALEMTUZUMAB AS IN VIVO PURGING TOOL FOR PATIENTS WITH ADVANCED CHRONIC LYMPHOCYTIC LEUKEMIA 216
Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium. 216
CD229 expression on bone marrow plasma cells from patients with multiple myeloma and monoclonal gammopathies of uncertain significance 216
WT1 GENE EXPRESSION IS SIGNIFICANTLY INHIBITED BY VORINOSTAT AND BORTEZOMIB IN MYELOPROLIFERATIVE/MYELODISPLASTIC DISEASES 215
Activity of different revertant agents on multidrug resistance: in vitro evaluation of their combination 215
Immunomodulators and enzymes of purine metabolism in human lymphocytes 214
Binding of GC (VDBP) to membranes of human B lymphocytes following stripping of extant protein. 214
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma 214
Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial 214
Preparation of stable dispersion of barium titanate nanoparticles: Potential applications in biomedicine 214
β-Cell inflammation in human type 2 diabetes and the role of autophagy 213
Combined unfavourable polymorphisms ofhOCT1 and ABCG2 are responsible for delayed complete cytogenetic response during imatinib treatment. 213
Boron nitride nanotubes and primary human osteoblasts: in vitro compatibility and biological interactions under low frequency ultrasound stimulation 213
Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms 212
La storia della Facoltà di Medicina e Chirurgia 212
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 211
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. 210
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen 209
Mesodermal progenitor cells (MPCs) differentiate into mesenchymal stromal cells (MSCs) by activation of Wnt5/calmodulin signalling pathway. 209
Human dental pulp stem cells protect mouse dopaminergic neurons against MPP+ or rotenone. 209
HOX and TALE signatures specify human stromal stem cell populations from different sources. 209
Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. 209
Dipeptidyl-Peptidase 4 (Cd26): a Possible Therapeutic Target in Covid-19 209
Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). 208
NEUROENDOCRINE MODULATION OF ALLOGRAFT REJECTION BY DOPAMINE AGONISTS 207
The effects of lithium and rubidium on human leukocyte functions 207
Expression of p170 protein in multiple myeloma : a clinical study 207
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. 207
EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES) 207
Reversing of chlorambucil resistance by ethacrynic acid in a B-CLL patient 206
A case of Staphylococcal toxic shock syndrome with expansion of TCR alphaBeta+, CD4/CD8 double negative lymphocytes 206
Correction: Use of Autologous Human mesenchymal Stromal Cell/Fibrin Clot Constructs in Upper Limb Non-Unions: Long-Term Assessment. 206
Synergistic effects of alpha interferon and 1,25 dihydroxyvitamin D3: Preliminary evidence suggesting that interferon induces expression of the vitamin receptor 205
The combination of rituximab and bendamustine as first-line treatment is highly effective in the eradicating minimal residual disease in follicular lymphoma: An Italian retrospective study 205
Modulation of glycoprotein P in the primary culture of rat hepatocytes 204
Oral cyclophosphamide therapy for patients with residual or relapsed indolent-type lymphoma after initial treatment for aggressive lymphomas. A sub-group of patients with apparent transformed indolent lymphoma. 204
Unexpected cardiotoxicity in haematological bortezomib treated patients 204
Thrombocytopenic purpura: an unusual complication of eradication therapy for Helicobacter pylori 203
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol. 2010 Apr;21(4):851-4. Epub 2009 Oct 13. 203
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). 203
Multiple small bowel perforations due to invasive aspergillosis in a patient with acute myeloid leukemia: case report and a systematic review of the literature 203
Totale 26.178
Salva come PNG Salva come JPEG
Categoria #
all - tutte 285.631
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 285.631
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20226.734 0 0 209 573 1.359 938 183 326 349 184 563 2.050
2022/20238.869 1.205 1.188 606 827 958 1.188 82 713 1.401 40 585 76
2023/20249.716 933 767 835 449 996 1.136 216 176 89 3.378 135 606
2024/202519.146 68 710 138 1.192 1.837 1.825 1.575 1.079 1.821 2.568 2.056 4.277
2025/202619.325 1.223 2.561 2.222 1.543 1.986 2.007 3.073 888 968 1.867 690 297
2026/20274.874 820 1.699 2.355 0 0 0 0 0 0 0 0 0
Totale 105.979